Table 1.
Antibodies used for cell characterisation.
Figure 1.
Phenotypic appearances of primary cultures.
A: Brightfield demonstrating cobblestone monolayer; immunoflourescent images with antibodies targeted against: B: FITC-anti-pancytokeratin; C: Alexafluor 596 anti-CA125; D: Alexflour 488 anti-EpCAM; E: Alexafluor 596 anti-MOC 31; F: Alexaflour 596 anti-Vimentin
Table 2.
Patient demographics by histological subtype.
Figure 2.
Antigen expression in primary cultures.
PCO 158 A: Immunohistochemical detection of CA125 in FFPE tissue; B: Immunofluourescent detection of CA125 with Alexaflour596 from corresponding primary culture
Figure 3.
Growth curves for 6 representative PCO cultures (PCO143, 146, 149, 164,167 and 168).
The mean and SD of 6 repeats for each time point is plotted, normalised to day 1.
Figure 4.
Brightfield images of PCO 163 which was derived from solid tissue explant.
A: Passage 0 at 48 hours; B: Passage 0 at 72 hours; C: Passage 1 at 14 days
Figure 5.
Brightfield images of PCO 162 demonstrating the effects of selective seeding.
A: Epithelial cell growth from supernatant removed 30 minutes after initial plating (×20 magnification); B: Cells adhering during the initial 30 minute incubation were almost entirely fibroblastic (×10 magnification).
Table 3.
Primary culture outcomes following transport.
Table 4.
Comparison between the characterisation results from immunoflourescent microscopy (IF) and ImagestreamX (ISX).
Figure 6.
A: ImagestreamX cell plot of representative cells demonstrating the three major cellular sub-populations within ascitic fluid, ; i) CK positive only, ii) CK and CA125 positive and iii) EpCAM, CK and CA125 positive. B: Sub-populations identified in the epithelial cell population in EOC ascitic fluid (n = the total number of epithelial cells identified in 10 ml of ascites).
Table 5.
HR DNA repair status of PCO culture with corresponding sensitivity to 10 µM Rucaparib.